Meeting
2013 ASCO Annual Meeting
Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?
Authors
Joanna Mangana
University Hospital Zurich, Dermatology, Zurich, Switzerland
Joanna Mangana , Simone M. Goldinger , Katja Schindler , Sima Rozati , Anna L. Frauchiger , Markus Rechsteiner , Holger Moch , Emanuela Romano , Katharina C. Kaehler , Olivier Michielin , Axel Hauschild , Christoph Hoeller , Reinhard Dummer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9025)
DOI
10.1200/jco.2013.31.15_suppl.9025
Abstract #
9025
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.
First Author: Olivier Jules van Not
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Retrospective study comparing survival when ipilimimab used with and without radiotherapy in patients with advanced melanoma.
First Author: Dominique Siobhan Parslow
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2023 ASCO Annual Meeting
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.
First Author: Geoffrey Thomas Gibney